Chen, Der-Yuan <br/><br/>
Response to: 'Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study' by Sanmarti et al.  [electronic resource] 

 -  Annals of the rheumatic diseases  Aug 2015 
 - e43 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/annrheumdis-2015-207543  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies--blood<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antirheumatic Agents--blood<br/>Arthritis, Rheumatoid--drug therapy<br/>Female<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Male<br/>Receptors, Tumor Necrosis Factor--therapeutic use